Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
The final analysis of the STELLAR-303 trial's non-liver metastases subgroup showed a non-statistically significant trend in overall survival favoring zanzalintinib plus atezolizumab, with a hazard ratio of 0.83 and P=0.1185. Median overall survival was 15.9 months for the combination arm compared to 12.7 months for regorafenib, with no new safety signals identified in the subgroup.
Key figures
- Drug Name
- Zanzalintinib
- Phase Of Trial
- Phase 3
- P value
- 0.1185
- Pdufa date
- December 3, 2026
- Hazard ratio
- 0.83
- Median os control
- 12.7 months
- Confidence interval
- 0.66–1.05
- Median os combination
- 15.9 months
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.